Vitara Biomedical
Vitara Biomedical is dedicated to transforming neonatal care by developing a therapeutic platform to support premature infants, aiming to improve their quality of life and reduce mortality.
Company Vision
Vitara Biomedical aims to transform neonatal care by offering newborns and their families a lifetime of possibilities. The company's goal is to protect more preterm infants and improve their quality of life by reducing mortality and comorbidities.
Premature Birth Statistics
Approximately 15 million babies are born preterm globally each year, and premature birth is the leading cause of death in children under 5 years old. The economic burden of preterm births in the US alone is estimated to be $26 billion. Babies born before 37 weeks of gestation are considered preterm and often face significant health challenges.
Technological Innovation
Vitara Biomedical is developing a therapeutic platform aimed at supporting premature infants. This next-generation platform therapy is designed to provide a comfortable and stable environment for premature babies to acclimate outside the womb while continuing to develop, inspired by natural physiological processes. The technology aims to improve the condition of underdeveloped lungs and supports smoother transitions into life outside the womb.
Location
Vitara Biomedical is located at 2301 Chestnut Street, 4th Floor, Philadelphia, PA 19103. This location serves as the hub for the company's operations, including research and development of their innovative neonatal care technologies.